Complete metabolic response following anaplastic lymphoma kinase ( ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results-Reference-Cited by-同舟云学术

Complete metabolic response following anaplastic lymphoma kinase ( ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results

Published:2021-08 Issue:8 Volume:51 Page:1355-1356
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Chazan Grace¹^ORCID,Forbes Danielle²,Murugasu Anand³,Wong Hui‐Li¹⁴,Solomon Benjamin¹

Affiliation:

1. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Department of Medical Oncology Western Health Melbourne Victoria Australia

3. Department of Pathology Royal Melbourne Hospital Melbourne Victoria Australia

4. Personalised Oncology Division The Walter and Eliza Hall Institute of Medical Research Melbourne Victoria Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15450

Reference6 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

2. Anaplastic lymphoma kinase (ALK) partners identified by next‐generation sequencing in Chinese patients with solid tumors;Yang S;J Clin Oncol,2020

3. Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

4. Comparison of Reverse Transcription-Polymerase Chain Reaction, Immunohistochemistry, and Fluorescence In Situ Hybridization Methodologies for Detection of Echinoderm Microtubule-Associated Proteinlike 4–Anaplastic Lymphoma Kinase Fusion–Positive Non–Small Cell Lung Carcinoma: Implications for Optimal Clinical Testing

5. Patient‐centered approach to benefit‐risk characterization using number needed to benefit and number needed to harm: advanced non‐small‐cell lung cancer;Raju GK;JCO Clin Cancer Inform,2020